Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 vs Futuximab vs Modotuximab in Refractory mCRC
NCT03549338Phase 2Terminated
- Sponsor
- Symphogen
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of futuximab + modotuximab in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Symphogen. Primary endpoint: Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence at 4 months. Started Nov 2018; status: terminated.
02
Drugs
futuximab + modotuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03549338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549338.